Mickael Lescroart, Hélène Kemp, Olivier Imauven, Jean Herlé Raphalen, François Bagate, Julien Schmidt, Nahema Issa, Maxens Decavele, Anne-Sophie Moreau, Fabienne Tamion, Bruno Mourvillier, Laure Calvet, Emmanuel Canet, Christine Lebert, Stephanie Pons, Guillaume Lacave, Florent Wallet, Hadrien Winiszewski, Hamid Merdji, Marc Pineton De Chambrun, Laurent Argaud, Antoine Kimmoun, Guillaume Dumas, Lara Zafrani
{"title":"Cardiogenic shock in patients with active onco-hematological malignancies: A multicenter retrospective study.","authors":"Mickael Lescroart, Hélène Kemp, Olivier Imauven, Jean Herlé Raphalen, François Bagate, Julien Schmidt, Nahema Issa, Maxens Decavele, Anne-Sophie Moreau, Fabienne Tamion, Bruno Mourvillier, Laure Calvet, Emmanuel Canet, Christine Lebert, Stephanie Pons, Guillaume Lacave, Florent Wallet, Hadrien Winiszewski, Hamid Merdji, Marc Pineton De Chambrun, Laurent Argaud, Antoine Kimmoun, Guillaume Dumas, Lara Zafrani","doi":"10.1016/j.jcrc.2025.155028","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Onco-hematological (OH) patients face significant cardiovascular risks due to malignancy and drug toxicity. Data are limited on the characteristics and outcomes of OH patients with cardiogenic shock (CS) in intensive care units (ICUs).</p><p><strong>Methods: </strong>This multicenter retrospective study included 214 OH patients with CS across 22 ICUs (2010-2021). The objectives were to (i) identify risk factors for 30-day mortality, (ii) describe early and long-term outcomes, and (iii) assess the prognostic impact of malignancy by comparing OH patients to a control group of CS patients.</p><p><strong>Results: </strong>The 30-day survival rate was 44.8 %. Multivariate analysis identified previous cardiomyopathy (OR = 1.61), acute kidney injury (OR = 1.62), lactate levels (OR = 1.08 per 1 mmol/L), pulmonary embolism (OR = 3.04), invasive mechanical ventilation (OR = 3.48), and epinephrine use (OR = 2.09) as factors associated with 30-day mortality. Among ICU survivors, 54 % were alive at 1 year with a median left ventricular ejection fraction of 52 %. OH malignancy was significantly associated with 30-day mortality (HR 2.54).</p><p><strong>Conclusion: </strong>The prognosis for OH patients with CS in the ICU is poor, with epinephrine use associated with worse outcomes. Further research is needed to refine risk stratification and improve treatments for this population.</p>","PeriodicalId":15451,"journal":{"name":"Journal of critical care","volume":"87 ","pages":"155028"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of critical care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jcrc.2025.155028","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Onco-hematological (OH) patients face significant cardiovascular risks due to malignancy and drug toxicity. Data are limited on the characteristics and outcomes of OH patients with cardiogenic shock (CS) in intensive care units (ICUs).
Methods: This multicenter retrospective study included 214 OH patients with CS across 22 ICUs (2010-2021). The objectives were to (i) identify risk factors for 30-day mortality, (ii) describe early and long-term outcomes, and (iii) assess the prognostic impact of malignancy by comparing OH patients to a control group of CS patients.
Results: The 30-day survival rate was 44.8 %. Multivariate analysis identified previous cardiomyopathy (OR = 1.61), acute kidney injury (OR = 1.62), lactate levels (OR = 1.08 per 1 mmol/L), pulmonary embolism (OR = 3.04), invasive mechanical ventilation (OR = 3.48), and epinephrine use (OR = 2.09) as factors associated with 30-day mortality. Among ICU survivors, 54 % were alive at 1 year with a median left ventricular ejection fraction of 52 %. OH malignancy was significantly associated with 30-day mortality (HR 2.54).
Conclusion: The prognosis for OH patients with CS in the ICU is poor, with epinephrine use associated with worse outcomes. Further research is needed to refine risk stratification and improve treatments for this population.
期刊介绍:
The Journal of Critical Care, the official publication of the World Federation of Societies of Intensive and Critical Care Medicine (WFSICCM), is a leading international, peer-reviewed journal providing original research, review articles, tutorials, and invited articles for physicians and allied health professionals involved in treating the critically ill. The Journal aims to improve patient care by furthering understanding of health systems research and its integration into clinical practice.
The Journal will include articles which discuss:
All aspects of health services research in critical care
System based practice in anesthesiology, perioperative and critical care medicine
The interface between anesthesiology, critical care medicine and pain
Integrating intraoperative management in preparation for postoperative critical care management and recovery
Optimizing patient management, i.e., exploring the interface between evidence-based principles or clinical insight into management and care of complex patients
The team approach in the OR and ICU
System-based research
Medical ethics
Technology in medicine
Seminars discussing current, state of the art, and sometimes controversial topics in anesthesiology, critical care medicine, and professional education
Residency Education.